S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

NASDAQ:NVUSNovus Therapeutics Stock Price, Forecast & News

$0.45
-0.02 (-4.26 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.44
Now: $0.45
$0.47
50-Day Range
$0.45
MA: $0.61
$1.31
52-Week Range
$0.25
Now: $0.45
$1.45
Volume415,570 shs
Average Volume676,980 shs
Market Capitalization$7.23 million
P/E RatioN/A
Dividend YieldN/A
Beta3.2
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Read More
Novus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVUS
CUSIPN/A
Phone949-238-8090

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.73 per share

Profitability

Net Income$-16,010,000.00

Miscellaneous

EmployeesN/A
Market Cap$7.23 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive NVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.

Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions

How has Novus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Novus Therapeutics' stock was trading at $0.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVUS stock has increased by 7.1% and is now trading at $0.45. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novus Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novus Therapeutics.

When is Novus Therapeutics' next earnings date?

Novus Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Novus Therapeutics.

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics Inc (NASDAQ:NVUS) announced its quarterly earnings results on Friday, May, 15th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.31. View Novus Therapeutics' earnings history.

What price target have analysts set for NVUS?

3 brokers have issued 12-month price targets for Novus Therapeutics' stock. Their forecasts range from $0.60 to $3.25. On average, they anticipate Novus Therapeutics' share price to reach $1.95 in the next year. This suggests a possible upside of 333.3% from the stock's current price. View analysts' price targets for Novus Therapeutics.

Has Novus Therapeutics been receiving favorable news coverage?

Media coverage about NVUS stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novus Therapeutics earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Novus Therapeutics.

Who are some of Novus Therapeutics' key competitors?

What other stocks do shareholders of Novus Therapeutics own?

Who are Novus Therapeutics' key executives?

Novus Therapeutics' management team includes the following people:
  • Mr. Gregory J. Flesher, CEO & Director (Age 49)
  • Dr. Catherine C. Turkel, Pres (Age 58)
  • Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 54)

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

How do I buy shares of Novus Therapeutics?

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $0.45.

How big of a company is Novus Therapeutics?

Novus Therapeutics has a market capitalization of $7.23 million. The biopharmaceutical company earns $-16,010,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

What is Novus Therapeutics' official website?

The official website for Novus Therapeutics is novustherapeutics.com.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.